Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 11:13:1079884.
doi: 10.3389/fimmu.2022.1079884. eCollection 2022.

Temporal trends of COVID-19 antibodies in vaccinated healthcare workers undergoing repeated serological sampling: An individual-level analysis within 13 months in the ORCHESTRA cohort

Giulia Collatuzzo  1 , Giuseppe De Palma  2 , Francesco S Violante  1   3 , Stefano Porru  4 , Francesca Larese Filon  5 , Eleonora Fabianova  6 , Concepción Violán  7   8   9   10 , Luigi Vimercati  11 , Mihaela Leustean  12 , Marta Maria Rodriguez-Suarez  13 , Emanuele Sansone  3 , Emma Sala  14 , Carlotta Zunarelli  1 , Vittorio Lodi  3 , Maria Grazia Lourdes Monaco  15 , Gianluca Spiteri  15 , Corrado Negro  5 , Jana Beresova  6 , LucÌa A Carrasco-Ribelles  7 , Silvio Tafuri  11 , Shuffield S Asafo  1 , Giorgia Ditano  1 , Mahsa Abedini  1 , Paolo Boffetta  1   16
Affiliations

Temporal trends of COVID-19 antibodies in vaccinated healthcare workers undergoing repeated serological sampling: An individual-level analysis within 13 months in the ORCHESTRA cohort

Giulia Collatuzzo et al. Front Immunol. .

Erratum in

Abstract

Short summary: We investigated changes in serologic measurements after COVID-19 vaccination in 19,422 subjects. An individual-level analysis was performed on standardized measurements. Age, infection, vaccine doses, time between doses and serologies, and vaccine type were associated with changes in serologic levels within 13 months.

Background: Persistence of vaccine immunization is key for COVID-19 prevention.

Methods: We investigated the difference between two serologic measurements of anti-COVID-19 S1 antibodies in an individual-level analysis on 19,422 vaccinated healthcare workers (HCW) from Italy, Spain, Romania, and Slovakia, tested within 13 months from first dose. Differences in serologic levels were divided by the standard error of the cohort-specific distribution, obtaining standardized measurements. We fitted multivariate linear regression models to identify predictors of difference between two measurements.

Results: We observed a progressively decreasing difference in serologic levels from <30 days to 210-240 days. Age was associated with an increased difference in serologic levels. There was a greater difference between the two serologic measurements in infected HCW than in HCW who had never been infected; before the first measurement, infected HCW had a relative risk (RR) of 0.81 for one standard deviation in the difference [95% confidence interval (CI) 0.78-0.85]. The RRs for a 30-day increase in time between first dose and first serology, and between the two serologies, were 1.08 (95% CI 1.07-1.10) and 1.04 (95% CI 1.03-1.05), respectively. The first measurement was a strong predictor of subsequent antibody decrease (RR 1.60; 95% CI 1.56-1.64). Compared with Comirnaty, Spikevax (RR 0.83, 95% CI 0.75-0.92) and mixed vaccines (RR 0.61, 95% CI 0.51-0.74) were smaller decrease in serological level (RR 0.46; 95% CI 0.40-0.54).

Conclusions: Age, COVID-19 infection, number of doses, time between first dose and first serology, time between serologies, and type of vaccine were associated with differences between the two serologic measurements within a 13-month period.

Keywords: COVID-19 vaccination; antibodies; health care workers; serial serology; temporal trends.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timing of vaccination and serologic measurements by cohort.
See this image and copyright information in PMC

References

    1. Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines (2016) 15(12):1519–33. doi: 10.1080/14760584.2016.1198259 - DOI - PMC - PubMed
    1. Castellino F, Galli G, Del Giudice G, Rappuoli R. Generating memory with vaccination. Eur J Immunol (2009) 39(8):2100–5. doi: 10.1002/eji.200939550 - DOI - PubMed
    1. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. . Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory b cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A (2009) 106(19):7962–7. doi: 10.1073/pnas.0903181106 - DOI - PMC - PubMed
    1. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol (2019) 10:594. doi: 10.3389/fimmu.2019.00594 - DOI - PMC - PubMed
    1. de Vries RD, Rimmelzwaan GF. Viral vector-based influenza vaccines. Hum Vaccin Immunother (2016) 12(11):2881–901. doi: 10.1080/21645515.2016.1210729 - DOI - PMC - PubMed

Publication types